Navigation Links
Model Predicts Colon Cancer Inheritable Genetic Defects

Researchers from the Johns Hopkins University and other institutions have developed a new prediction model for genetic defects known as Lynch syndrome// , which predisposes families to develop colorectal cancer. The model, called MMRpro, is based on an individual’s detailed family history of colorectal and endometrial cancer, as well as knowledge of how genetic mutations manifest themselves—in the form of tumors. It can assess a person’s probability of carrying a particular defect within so-called mismatch repair genes. The study is published in the September 27, 2006, issue of the Journal of the American Medical Association (JAMA).

“Genetic defects can be passed from parents to their children; as a result, colon cancer runs in families. Our model will help identify individuals likely to have particular genetic defects. The results will give them useful information about their colon cancer risk before they decide whether to undergo invasive screenings or expensive genetic testing,” said Sining Chen, PhD, lead author of the study and an assistant professor in the Johns Hopkins Bloomberg School of Public Health’s Department of Environmental Health Sciences.

Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer, is characterized by the inheritance of defects in the MLH1, MSH2 and MSH6 genes. These three genes help repair mismatches that can occur during the duplication of the genetic code when new cells are made, and are known as mismatch repair (MMR) genes. Of the projected 600,000 MMR mutation carriers in the United States, each has approximately a 50 percent chance of being diagnosed with colorectal cancer by age 70. Women also have a 50 percent chance of developing endometrial cancer, explained Giovanni Parmigiani, PhD, senior author of the study and a professor of oncology, biostatistics and pathology at Johns Hopkins University.

The researchers applied MMRpro software to 279 individuals’ family histories. The st udy participants were tested with sensitive laboratory mutation-detection techniques. MMRpro predictions were compared to the laboratory test results, as well as predictions made with widely used assessment guidelines.

The researchers found that MMRpro more accurately predicted mutation carriers than two other assessment tools—the Bethesda guidelines and the Amsterdam criteria— that are currently available to families faced with the possibility that they have inherited the genetic defects related to colon cancer. MMRpro can identify more mutation carriers and fewer non-carriers than other assessment tools. MMRpro was able to access individuals who already have cancer as well as those who do not. Existing assessment tools can only be applied to individuals with cancer. In addition, certain MMR genetic mutations are hard to detect in laboratory tests. MMRpro was able to provide a useful risk assessment when conventional laboratory tests did not find a genetic mutation.

“Colorectal cancer is the second largest cause of cancer deaths in the US. It is also one of the most preventable forms of cancer. We expect that MMRpro will contribute significantly to controlling the disease by prioritizing high risk individuals for intensive screening and early detection,” said Chen. “We also expect that it will be a tool for investigators interested in understanding inherited colorectal cancer, allowing them to select families to more efficiently study these genetic defects.”

Source-Newwise
SRM
'"/>




Related medicine news :

1. Researchers Develop Mouse Model Of Brain Tumor
2. New Model for understanding Tumor Metastasis
3. Mathematical Model Can Now Help Predict Asthma Risk
4. Model Kate Moss - Re-Birth After Humiliation
5. Womens Self-Esteem Not Lowered By Seeing Ultra Thin Models
6. India Can Become A Role Model In Combating HIV Infections
7. Mouse Models To Determine The Cause Of Aggressive Leukemia
8. Aussie Model Macpherson Hated Tall Figure
9. Mouse Model Beneficial to Study of Head and Neck Cancer
10. Tamil Nadu Emerging As Model State In Public Health Care: Governor
11. iSTART Brain Model Reveals the possible Cause of Autism
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/17/2019)... ... ... Whole Foods Market, along with Austin leaders, has joined forces with Blue Zones ... assessment by the Blue Zones team of the Austin Metro area and population that ... work, grow up, and grow old. , Blue Zones is based on research and ...
(Date:10/15/2019)... , ... October 15, 2019 , ... ... FDA’s Most Recent IFU Guidance , **An FDAnews Webinar**, Tuesday, October 29, 2019, ... for Use (IFU) guidance have on new drug applications and biologics license applications? ...
(Date:10/15/2019)... (PRWEB) , ... October 15, 2019 , ... Nashville Fertility ... be the latest fertility doctor to join the practice. In addition to treating general ... syndrome (PCOS). , The team at NFC looks forward to Dr. Van Heertum joining ...
(Date:10/11/2019)... ... ... A Topping Out event was hosted today at the construction site of the ... The event celebrated reaching the final height of the structure set to open in ... kind in Texas, STA’s facility will be home to an organ recovery center including ...
(Date:10/10/2019)... ... 10, 2019 , ... Caring.com, a leading senior care referral service with Family ... for Seniors to Live. All 50 states and 302 cities in the U.S. were ... development. , According to the U.S. Census Bureau , almost 20 million ...
Breaking Medicine News(10 mins):
(Date:10/19/2019)... ... October 18, 2019 , ... Beginnings Treatment Centers, a ... as the official sponsor of the Alcohol and Other Drug Awareness Week ... students to make informed decisions around alcohol and other drugs through individual education and ...
(Date:10/17/2019)... (PRWEB) , ... October 17, 2019 , ... ... patients with neuroblastoma, a deadly pediatric nerve cancer, who would otherwise have no ... , Neuroblastoma is one of the most common and aggressive pediatric nervous system ...
(Date:10/15/2019)... ... October 14, 2019 , ... ... linearity and calibration verification kit, for Roche cobas® analyzers, Order No. 507ro. ... B (Apo-B). Each VALIDATE® LP2 kit, liquid, ready-to-use, and prepared using ...
Breaking Medicine Technology: